Colloquium: “Keeping Patients with Immigration Concerns in HIV Care and Services”

October 12, 2017 – CHIPTS October installment of the Colloquia series focused on patients with immigration concerns (specifically the Latino community) who are living with HIV/AIDS and are at risk of falling out of care.

Tom Donohoe, MBA, presented on the relevancy of immigration concerns for patients living with HIV/AIDS while Alonso Bautista, MA, MFTI, examined the psychosocial stressors of being (or having loved ones who are) undocumented as well as especially those living with HIV in the current social climate. Ayako Miyashita, JD, closed the presentation by discussing the legalities associated with serving those with immigration concerns and the policies in place.

Download the flyer and slides below and check out the entire lecture on Youtube:

2017 October Colloquium Flyer
2017 October Colloquium Slides

CHIPTS hosts a monthly HIV Research and Community Colloquia Series in collaboration with the Los Angeles County Commission on HIV to highlight current issues and conversations surrounding HIV. Click here for past lectures and check out the events page for more information on future Colloquia presentations!

SAMHSA Awards $166 Million for HIV Prevention and Treatment

October 5, 2017 – The Substance Abuse and Mental Health Services Administration (SAMHSA) has awarded grants totaling $166 million over five years through its Targeted Capacity Expansion-HIV (TCE-HIV) Program and its Prevention Navigator Program. The grant funding will be used to prevent HIV among high-risk populations and to treat co-occurring behavioral health disorders and HIV.

Grantees will use the funds for activities such as outreach, screening, prevention and treatment. “Our efforts in vulnerable communities have shown us that prevention works,” said Dr. Elinore McCance-Katz, Assistant Secretary for Mental Health and Substance Use. “This funding will be used to increase access to a range of services important to prevention, recovery and healthy living.”

(Full Article)

Stimulant Use: Harm Reduction, Treatment, and Future Directions Conference

September 25, 2017 – the Drug Policy Alliance (DPA) hosted the “Stimulant Use: Harm Reduction, Treatment, and Future Directions” conference to engage participants in dialogue about stimulant use. Within the walls of the Japanese American National Museum in downtown Los Angeles, harm reduction providers, social service providers, researchers, policy makers, the LGBTQ community, and people who use stimulants explored the complexities of stimulant use through a series of panels.

CHIPTS Center Director and CBAM Executive Director, Dr. Steven Shoptaw PhD, gave the closing remarks at the conference after a day full of rich conversation surrounding stimulant use.

You can read more on the report here and download the full report of the conference here:  Stimulant Use: Harm Reduction, Treatment, and Future Directions Conference - Report

LAC DPH Health Alert: Outbreak of Hepatitis A in Los Angeles County among the Homeless and People who use Illicit Drugs

September 19, 2017 –This message is intended for infectious disease, primary care, emergency medicine, urgent care, emergency medical services, and healthcare personnel who provide services to the homeless or drug using populations.
Please distribute as appropriate.
Key Messages
• The Los Angeles County Department of Public Health (LAC DPH) is declaring an outbreak of Hepatitis A virus (HAV) among persons who are homeless and/or use illicit (injection and non-injection) drugs.
• LAC DPH has further expanded its HAV vaccine recommendations during the outbreak. HAV vaccination is now recommended for persons who are homeless and/or who use illicit drugs and to persons who have frequent close contact with the homeless or drug-using populations. This includes those who handle or serve food or who provide personal care, janitorial, maintenance, or sanitation services to these populations.
• Suspect cases of HAV should be reported immediately by phone, while the patient is still at the clinical facility, in order to facilitate an on-site interview by a public health investigator and prophylaxis of contacts; phone 888-397-3993. After hours call: 213-974-1234.

• Vaccination and soap and water hand hygiene are the best prevention against HAV.

Current Situation
LAC DPH has identified 2 cases of community acquired HAV in homeless persons residing in LA County for whom no clear recent links to San Diego or Santa Cruz counties can be established. In addition, 8 cases of HAV have recently been linked to the outbreaks in San Diego and Santa Cruz. These new cases indicate that spread may be occurring among homeless persons in LA County. With the identification of new cases with no known links to other outbreak jurisdictions, LAC DPH is declaring a local outbreak. Identification of new HAV cases continues in San Diego and Santa Cruz counties in persons who are homeless and/or using illicit drugs.

In the outbreaks in all three counties, HAV is primarily being transmitted person-to-person through close contact or through contact with a fecally contaminated environment. The fatality rate of HAV in this homeless and illicit drug use population is higher than the rate observed in healthy individuals.

Actions Requested of Providers:
• Suspect HAV infection in patients who have close contact with or who are homeless/intermittently homeless and/or who use illicit drugs who have abrupt onset of prodromal symptoms (nausea, anorexia, fever, malaise, or abdominal pain) and jaundice or elevated serum aminotransferase levels. A complete serology panel with testing for hepatitis A (for acute HAV order IgM), B, and C is recommended in symptomatic patients. Please hold an additional serology specimen which DPH will collect. HIV testing is also recommended for those with an undocumented HIV-status. Do not test asymptomatic people for HAV infection as the false positive rate is high.
• Promptly report all suspect and confirmed HAV cases to the LAC DPH Morbidity Unit by calling 888-397-3993. After hours call 213-974-1234. Providers must report while suspected cases are still at the healthcare facility to facilitate immediate interview by a public health investigator and prophylaxis of contacts. Any patient presenting with jaundice or hepatitis symptoms and who reports being homeless within the last 2 months or using illicit drugs should be reported immediately.

• Do not discharge patients to the street who are diagnosed with HAV until at least a week after the onset of jaundice. Health Officer orders are available to facilitate holding patients for discharge planning. For assistance call: 888-397-3993 during business hours and 213-974-1234 after hours.
• Provide post-exposure prophylaxis (PEP) for close contacts of confirmed HAV cases as directed by LAC DPH. Susceptible people exposed to HAV should receive PEP as soon as possible within 2 weeks of last exposure. Single-antigen HAV vaccine and immune globulin (IG) are effective HAV PEP therapies; recommendations for PEP vary with patient age and risk for severe infection and can be found on the CDPH Hepatitis A Postexposure Prophylaxis Guidance Quicksheet. Vaccination with single antigen HAV vaccine generally is recommended as part of the PEP regime to provide more long-lasting protection; exceptions include infants and in uncommon situations when vaccination is contraindicated. LAC DPH will assist in the management of contacts.
• Provide HAV vaccine to persons who are homeless and/or who use illicit drugs and to persons who have frequent close contact with the homeless or drug-using populations. This includes those who handle or serve food or who provide personal care, janitorial, maintenance, or sanitation services to these populations. Serologic testing for HAV immunity is not recommended prior to vaccination. Vaccinate with either single antigen HAV vaccine or the combined HAV/HBV (Twinrix) vaccine. See the HAV Vaccine Resources below for more information regarding vaccine coverage and availability.

HAV Vaccine Resources
Medi-Cal: HAV vaccine is covered for patients enrolled in both fee-for-service and managed care plans. Vaccine administration is covered if administered in a provider’s office or by an in-network pharmacy. No prior authorization is required. Patients or those assisting them can call the plan’s member services number listed on the back of their Medi-Cal Benefits Identification Card to obtain information on pharmacy services. Prior to referring a patient to an in-network pharmacy for HAV vaccination, please contact the pharmacy to verify vaccine availability.

AIDS Drug Assistance Program (ADAP): HAV vaccine is included on the ADAP formulary.

LAC DPH Clinics: Free HAV vaccine is available at the LAC DPH Public Health Centers for any at-risk people. Visit http://publichealth.lacounty.gov/chs/Docs/ImmSchedule.pdf for clinic times and locations.

In addition, LAC DPH is conducting outreach clinics to offer HAV vaccine in conjunction with community partners that serve the homeless community.

For questions regarding HAV vaccine and/or supply related to this outbreak contact the LAC DPH Immunization Program at 213-351-7800.
For Questions

Los Angeles County DPH Acute Communicable Disease Control Program:
Weekdays 8:30am-5pm: call 213-240-7941
After hours: call 213-974-1234 and ask for the physician on call.

Reporting for Residents of Long Beach and Pasadena
Long Beach Health and Human Services:
Weekdays 8am-5pm: call 562-570-4302
After hours: call 562-435-6711 and ask for Communicable Disease Officer.

Pasadena Public Health Department:
Weekdays 8am-5pm: call the Communicable Disease Control Program 626-744-6089
After hours: call 626-744-6043.

This Health Alert was sent by Dr. Sharon Balter, Chief, Acute Communicable Disease Control Program, Los Angeles County Department of Public Health

Colloquium: “Secret Shopper Evaluation of HIV Testing Services for Youth in LAC”

img_0379September 14, 2017 — A collaborative of 6 youth-serving agencies in Los Angeles evaluated the youth-friendliness of HIV testing services available. A total of 19 testing sites across the county were evaluated by youth utilizing a tool that focused on four core areas (confidentiality and privacy; youth-centered counseling; sex-positive health messaging; and youth-friendly environment). The findings of the evaluation highlight the need to update HIV testing training, protocols, and policies to focus on these core areas, which impact the acceptability of testing services for youth. This evaluation is a first step in improving the quality of services available for youth in Los Angeles. In addition, the presentation will include a discussion about the barriers and facilitators to accessing local HIV testing services among youth.

2017 September Colloquium Flyer
2017 September Colloqium Slides

CHIPTS hosts a monthly HIV Research and Community Colloquia Series in collaboration with the Los Angeles County Commission on HIV to highlight current issues and conversations surrounding HIV. Click here for past lectures and check out the events page for more information on future Colloquia presentations!

Fogarty Training Program Workshop in Hanoi – Community-Based Intervention Studies

2017-09-05_23-37-02September 8, 2017, Hanoi, Vietnam — During September 6th-8th, 2017, Faculty and researchers from academic institutions in Vietnam, researches from local NGOs, Ministry of Health Program Managers, Graduate students of Hanoi Medical University, and Fellows of the Vietnam Fogarty Training Program gathered together for a workshop series on “Community-Based Intervention Study in HIV/AIDS and Substance Abuse.”

The purpose was to improve understanding of various aspects of community-based intervention studies to identify and prevent and support treatment and care of HIV infections and substance abuse disorders and to appreciate challenges of designing and conducting a community-based intervention, and developing together.2017-09-06_20-03-34

Workshops ranged in a variety of topics such as Development and Delivery of Behavioral Interventions presented by CHIPTS Dr. Li Li who also presented Intervention Studies Involved Service Providers, Behavioral Interventions for Substance Abuse in the Setting of HIV by Dr. Professor Steve Shoptaw, and more.

2017-09-05_23-37-41Meanwhile Dr. Shoptaw also spoke on the Medications for Substance Abuse in the Setting of HIV while another CHIPTS faculty member, Dr. Chunqing Lin presented on An Overview of Implementation Science in Healthcare.

The conference concluded with feedback from the UCLA faculty for the attendees who had collaborated to create preliminary concepts on community-based interventions that are relevant for the context of Vietnam.

For more information on the Fogarty Training Program, its goals, and its global locations, check out their page under the Education tab!

IAS 2017 – Dr. Landovitz presents on the results of HPTN-077

July 25, 2017, Paris, France – Dr. Landovitz, CHIPTS Co-Director, spoke on the “Enhancing the Impact of HIV Prevention” press conference regarding the findings of HPTN-077 at the 9th International AIDS Society Conference on HIV Science in Paris, France.

 

Photo ©IAS/Steve Forrest/Workers' Photos
Photo ©IAS/Steve Forrest/Workers’ Photos

A previous phase 2a study of US males that used a dose of 800mL of cabotegrovir administered every 3 months did not consistently meet the pharmacokinetics  standards. Due to this study, HPTN-077 studied not only a dosage of 800 mL in males and females administered every 3 months, but also a model dose of 600 mL every 8 weeks. HPTN-077 is a phase 2a study designed to measure the safety tolerability, acceptability, and pharmacokinetics of Cabotegravir.

Dr. Landovitz goes on to describe how HPTN-077 was conducted and its positive results, saying that they were “very supportive for moving forward into phase 3 efficacy studies with the 600 mL dose” noting that such a study was already in the field with HPTN-083 while HPTN-084 is currently in development.

The press conference included presentations from Jean-Michel Molina, Ayesha Kharsany, Andrew Grulich, Catherine Oldenburg, and moderator Linda-Gail Bekker and concluded with questions from the audience.

To see the entirety of Dr. Landovitz presentation, click on the photo below! Dr. Landovitz’s presentation begins at the the 7:05 mark.

Photo ©IAS/Steve Forrest/Workers' Photos
Photo ©IAS/Steve Forrest/Workers’ Photos

Matthew Feldman, PhD, MSW at CHIPTS Special Guest Seminar

Evaluating Services for People Living with HIV in New York City Using Ryan White Part A Data

Matthew Feldman, PhD, MSW
Senior Research Analyst
Care & Treatment/Research & Evaluation Unit
Bureau of HIV/AIDS Prevention & Control
New York City Dept. of Health & Mental Hygiene
Gotham Center

Thursday, May 25, 2017
12:00pm to 1:00pm

Matthew Feldman, Ph.D., M.S.W. is a Senior Research Analyst in the Care & Treatment Research & Evaluation Unit in the Bureau of HIV/AIDS Prevention and Control at the New York City Department of Health & Mental Hygiene. His primary responsibility is designing and implementing research and evaluation projects based on demographic, behavioral, and clinical data collected from PLWH who receive Ryan White Park A services. Dr. Feldman also has over 10 years of clinical practice experience working with a variety of populations, including PLWH, and he is an Adjunct Assistant Professor at the Columbia University School of Social Work where he teaches research and practice courses to Master’s students.

This event is sponsored by the California HIV/AIDS Policy Research Center at UCLA and the Center for HIV Identification, Prevention, and Treatment Services (NIMH grant MH058107).

[Download not found]

Brendan Quinn, PhD at CHIPTS Special Guest Seminar

Syndemic Structural and Drug Use Factors Contributing  to Marginalization, HIV , HIV Transmission and Viral Load Among mSTUDY Participants

Brendan Quinn, PhD

Fullbright Scholar

Visiting Research Fellow, UCLA

Research Fellow, Behavior & Health Risks Program, Bunet Institute, Australia

Thursday, June 29, 2017

2:30pm to 3:30pm

This presentation will discuss a longitudinal data analysis examining the impacts a longitudinal data analysis examining the impacts of four structural conditions (unemployment, incarceration, contact with healthcare providers, and unstable accommodations) on self -reported sexual HIV transmission risk behaviors and viral load among mSTUDY participants. The mSTUDY is a 5-year cooperative agreement (U01 DA036267) to establish a cohort of men who have sex with men (MSM) of color to investigate interactions between non-injection use of methamphetamine, cocaine, opiates and binge drinking and HIV transmission dynamics.

This event was made possible by funds from the Center for HIV Identification, Prevention, and Treatment Services (NIMH grant MH058107).

For copies of the presentation slides, please contact Dr. Brendan Quinn at brendan.quinn@burnet.edu.au

Planning for the Los Angeles County HIV/STD Strategy for 2020 and Beyond

The Los Angeles County Department of Public Health’s Division of HIV and STD Programs (DHSP) is hosting a community meeting, “Planning for the Los Angeles County HIV/STD Strategy for 2020 and Beyond.” This event will be held immediately following the Commission on HIV meeting at St. Anne’s Conference Center on July 13, 2017 at 10:00am.
Planning for the LAC HIV Strategy 2020 and Beyond - Flyer